Other candidate genes were chosen because they have a strong genetic link to the patient population being studied, such as C9orf72 expansion in ALS-clinic patients and FMR1 in FXTAS patients (McMillan et al., 2015; Shelton et al., 2017, 2016). This evidence concerns the gene FMR1 and fragile X-associated tremor/ataxia syndrome.